Purdue and Amneal OxyContin clash ends
15-08-2018
Purdue continues OxyContin patent battle
10-10-2017
Natee Meepian / iStockphoto.com
Purdue Pharma has settled another patent dispute involving pain drug OxyContin (oxycodone), just weeks after a suit against generics company Amneal Pharmaceuticals came to an end.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Purdue Pharma, Assertio Therapeutics, OxyContin, ANDA, FDA, patent, patent infringement, oxycodone, dismissal, Depomed
